within Pharmacolibrary.Drugs.V_Various.V03A_AllOtherTherapeuticProducts.V03AB35_Sugammadex;

model Sugammadex
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 1.4666666666666667e-06,
    adminDuration = 600,
    adminMass = 4 / 1000000,
    adminCount = 1,
    Vd = 0.011,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0072,
    k12 = 7.666666666666667e-07,
    k21 = 7.666666666666667e-07);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Sugammadex</td></tr><tr><td>ATC code:</td><td>V03AB35</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>4</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>11</td><td>L</td></tr>
    <tr><td>clearance:</td><td>88</td><td>mL/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Sugammadex is a selective relaxant binding agent used to reverse neuromuscular blockade induced by rocuronium or vecuronium during surgical procedures under general anesthesia. It is approved and widely used in clinical practice for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after single intravenous administration.</p><h4>References</h4><ol><li><p>de Kam, PJ, et al., &amp; van den Heuvel, M (2015). Pharmacokinetics of sugammadex 16 mg/kg in healthy Chinese volunteers. <i>International journal of clinical pharmacology and therapeutics</i> 53(6) 456–461. DOI:<a href=\"https://doi.org/10.5414/CP202234\">10.5414/CP202234</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25907172/\">https://pubmed.ncbi.nlm.nih.gov/25907172</a></p></li><li><p>Yuan, F, et al., &amp; Joel Woolf, E (2022). Pharmacokinetics of Sugammadex: An Open-Label, 3-Period, Fixed-Sequence, 3-Single-Doses Study in Healthy Chinese Subjects. <i>Clinical pharmacology in drug development</i> 11(3) 333–340. DOI:<a href=\"https://doi.org/10.1002/cpdd.1006\">10.1002/cpdd.1006</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34939354/\">https://pubmed.ncbi.nlm.nih.gov/34939354</a></p></li><li><p>Keating, GM (2016). Sugammadex: A Review of Neuromuscular Blockade Reversal. <i>Drugs</i> 76(10) 1041–1052. DOI:<a href=\"https://doi.org/10.1007/s40265-016-0604-1\">10.1007/s40265-016-0604-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27324403/\">https://pubmed.ncbi.nlm.nih.gov/27324403</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.V.V03AB35 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Sugammadex;
